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Poly-ADP-ribosylation-mediated degradation of ARTD1
by the NLRP3 inflammasome is a prerequisite for
osteoclast maturation
C Wang1,4, C Qu1,4, Y Alippe1, SL Bonar1, R Civitelli1, Y Abu-Amer2, MO Hottiger3 and G Mbalaviele*,1
Evidence implicates ARTD1 in cell differentiation, but its role in skeletal metabolism remains unknown. Osteoclasts (OC), the bone-
resorbing cells, differentiate from macrophages under the influence of macrophage colony-stimulating factor (M-CSF) and
receptor-activator of NF-κB ligand (RANKL). We found that M-CSF induced ADP-ribosyltransferase diphtheria toxin-like 1 (ARTD1)
auto-ADP-ribosylation in macrophages, a modification that marked ARTD1 for cleavage, and subsequently, for degradation upon
RANKL exposure. We established that ARTD1 proteolysis was NLRP3 inflammasome-dependent, and occurred via the proteasome
pathway. Since ARTD1 is cleaved at aspartate214, we studied the impact of ARTD1 rendered uncleavable by D214N substitution
(ARTD1D214N) on skeletal homeostasis. ARTD1D214N, unlike wild-type ARTD1, was resistant to cleavage and degradation during
osteoclastogenesis. As a result, ARTD1D214N altered histone modification and promoted the abundance of the repressors of
osteoclastogenesis by interfering with the expression of B lymphocyte-induced maturation protein 1 (Blimp1), the master regulator
of anti-osteoclastogenic transcription factors. Importantly, ARTD1D214N-expressing mice exhibited higher bone mass compared
with controls, owing to decreased osteoclastogenesis while bone formation was unaffected. Thus, unless it is degraded, ARTD1
represses OC development through transcriptional regulation.
Cell Death and Disease (2016) 7, e2153; doi:10.1038/cddis.2016.58; published online 24 March 2016
Osteoclasts (OC) are mature myeloid cells, specialized in the
removal of aged or damaged bonematrix, which is then replaced
by new bone by the osteoblasts.1 OC differentiate from
precursors of the monocyte/macrophage lineage under the
influence of systemic and local factors present in the bone
microenvironment.1 These factors funnel their inputs through the
essential OC regulators, macrophage colony-stimulating factor
(M-CSF), which generatesmitogenic and survival signals,2,3 and
receptor activator of NF-κB ligand (RANKL), whose actions
promote OC differentiation and function.4,5 M-CSF and RANKL
signaling cascades not only promote the expression of pro-
osteoclastogenic transcription factors such as microphthalamia-
associated transcription factor (Mitf),6 NF-κB,7 c-Fos,8 NFATc19
and B lymphocyte-induced maturation protein 1 (Blimp1),10 but
also suppress the expression of the repressors of OC formation,
including inhibitors of differentiation,11 V-maf avian musculoa-
poneurotic fibrosarcoma oncogene homolog B (MafB),12 inter-
feron regulatory factor-8 (IRF8)13 and LIMhomeobox 2 (Lhx2).14
Thus, OC differentiation is tightly regulated by redundant
negative mechanisms to avoid unnecessary osteolysis.
Biochemical signals that regulate OC are amplified and
propagated by post-translational protein modifications, mainly
phosphorylation,1,2 ubiquitination15 and SUMOylation.16
Another biochemical modification with potential impact on
OC biology is poly-ADP-ribosylation, termed PARylation. This
reaction is catalyzed by ADP-ribosyltransferases (ARTDs)
also known as poly(ADP-ribose) polymerases (PARPs).17
Some ARTDs cause the formation of poly-ADP-ribose (PAR)
by transferring several ADP-ribose units from nicotinamide
adenine dinucleotide (NAD+) onto acceptor proteins.
ADP-ribosyltransferase diphtheria toxin-like 1 (ARTD1, also
known as PARP1) is the prominent member of this family
involved in DNA repair, cell proliferation and survival.18–20
Emerging evidence suggests that ARTD1 also plays an
important role in cell fate determination through regulation of
transcription.21 Indeed, ARTD1 can PARylate transcription
factors, thereby affecting their transcriptional activity22–24
or affect gene expression through epigenetic regulation as
the negatively charged PAR that it attaches to core and
linker histones induce chromatin decondensation, thereby
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facilitating access of transcription factors to DNA sites.21 In
addition, ARTD1 can influence chromatin modification by
PARylating histones at residues that are also regulated by
methylation or acetylation.21 Thus, through direct actions on
transcription factors and indirect influence through epigenetic
mechanisms, ARTD1 may represent a homeostatic mechan-
ism that alters OC differentiation program.
ARTD1 is regulated by various post-translational modifica-
tions, including caspase-mediated proteolytic cleavage at
aspartate 214,25 auto-PARylation,26 SUMOylation27 and
ubiquitination,28 which was linked to ARTD1 degradation in
cancer cells. Evidence indicates that activation of the
NOD-like receptor (NLR) family, pyrin domain-containing
3 (NLRP3) inflammasome, a protein complex comprising
the adapter protein ASC and caspase-1, triggers cascade
that leads to ARTD1 cleavage.29,30 Despite ARTD1’s actions
in many tissues, its role in skeletal homeostasis remains
unknown as only a few studies have explored its function in
osteoclastogenesis in vitro.31–33 We found that ARTD1 was
degraded during OC differentiation. Conversely, expression of
ARTD1D214N, which was resistant to degradation, caused a
high bone mass phenotype owing to increased expression of
OC repressors, decreased OC differentiation and bone
resorption, while bone formation was unaltered.
Results
ARTD1 is degraded during OC formation through
PARylation-dependent mechanisms. M-CSF provides
growth and survival signals for cells of the OC lineage
through regulation of numerous pathways, including PI3K/Akt
and MAPK.1 Here, we found that M-CSF contained in CMG
media34 induced massive protein PARylation in mouse bone
marrow macrophages (BMM), an effect that was time-
(Figure 1a, bracket) and concentration- (Supplementary
Figure S1A) dependent, and was inhibited by two chemically
different inhibitors of ARTD1 and ARTD2, olaparib (olap) and
veliparib (velip) (Figure 1b, bracket) or Artd1 happloinsuffi-
ciency (Supplementary Figure S1B). RANKL decreased
protein PARylation in a time-dependent manner (Figure 1c,
bracket). Whereas M-CSF treatment did not affect ARTD1
protein levels (Figure 1d, and Supplementary Figures S1B,
S1C), RANKL treatment reduced ARTD1 protein abundance
(Figure 1e and f). In addition, p89 kDa fragment (p89), a
product of caspase-mediated cleavage of ARTD130,35 was
apparent at day 2 during the differentiation of RAW 264.7
cells (Figure 1e), but was not readily detectable in the
differentiation of primary BMM (Figure 1f). Thus, ARTD1 is
likely responsible for protein PARylation, which inversely
correlates with OC differentiation.
Pull-down studies using Af1521 macrodomains (Figure 1g),
which have high specificity and affinity for PARylated
proteins,36 and immunoprecipitation studies using anti-PAR
antibody (Figure 1h) showed a decline in the levels of
PARylated ARTD1 during OC differentiation. These results
suggest that PARylation regulates ARTD1 protein levels.
Indeed, in the 3-day OC cultures treated with olap, not only
ARTD1 PARylation was inhibited (Figure 1g, top panel), but
ARTD1 degradation was also prevented (Figure 1g, middle
panel). ARTD1 was degraded through the proteasome path-
way since a brief exposure for 3 h of OC cultures to MG-132,
a proteasome inhibitor, was able to attenuate ARTD1 loss
(Figure 1i). Unexpectedly, p89 remained undetectable even in
the presence of MG-132, suggesting slow accumulation of this
fragment in these experimental conditions. The protective
effect of olap was not due to blockade of OC differentiation
because if anything, the number of OC in inhibitor-treated
cultures scored at day 4 was higher than that of vehicle-treated
cultures counted at day 3 (data not shown). Collectively, these
data suggest that ARTD1 auto-modification is required for its
degradation during osteoclastogenesis.
ARTD1 cleavage at D214 is required for its degradation
during OC formation. We hypothesized that caspase-
mediated cleavage of ARTD1 at aspartate 214 is required
for osteoclastogenesis to proceed. Hence, we studied the
impact of ARTD1 rendered uncleavable by D214N substitu-
tion (ARTD1D214N) on skeletal homeostasis. First, to ensure
that ARTD1D214N is indeed uncleavable, we exposed
LPS-primed BMM to ATP, an activator of the NLRP3
inflammasome.30 Inflammasome activation caused a time-
dependent decline in ARTD1 abundance in WT BMM,
a response that inversely correlated with the levels of the
cleaved p89 kDa ARTD1 fragment (p89) (Figure 2a). In
contrast, activated inflammasome failed to induce the
cleavage of ARTD1D214N (Figure 2b). ARTD1 processing
did not occur in Nlrp3-deficient mice (Figure 2c) as
expected. Conversely, following LPS treatment, which
up-regulated NLRP3 as reported,29 ARTD1 protein levels
were reduced in BMM expressing constitutively activated
NLRP3 (NLRP3ca) inflammasome in the absence of exogen-
ously added ATP, but not control cells (Figure 2d). Moreover,
ARTD1D214N blocked NLRP3ca-induced OC formation
(Supplementary Figure S2). Thus, ARTD1D214N is resistant
to cleavage in response to various stimuli, including pro-
apoptotic cues as reported25 and NLRP3 inflammasome-
induced signals.
We previously reported that the NLRP3 inflammasome is
activated during RANKL-inducedOC formation in the absence
of exogenously added secondary inflammasome-activating
signals.37 Although ARTD1 is degraded during osteoclasto-
genesis, it is still unclear whether ARTD1 cleavage at D214 is
a prerequisite for its degradation during this process.
To understand the relationship between these two non-
mutually exclusive mechanisms, we monitored the fate of
WT and ARTD1D214N during OC formation. WT and
ARTD1D214N mRNA levels were unaltered during OC forma-
tion (Figure 2e), and ARTD1 protein levels were diminished by
day 3 of cultures in WT cells whereas those of ARTD1D214N
protein remained unchanged during OC formation (Figure 2f).
Occasionally, a fragment of ~ 78 kDa was observed in cells
expressing ARTD1D214N, suggesting that mutant ARTD1 is
proteolytically processed to some extent at a different site to
enable minimal osteoclastogenesis. Collectively, our results
also suggest that WT, but not ARTD1D214N is efficiently
degraded during this process. Consistent with a role for the
NLRP3 inflammasome in ARTD1 processing, ARTD1 was
degraded at a slower pace in NLRP3-deficient cells compared
with WT counterparts (Figure 2g).
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ARTD1 levels consistently declined by day 3 of OC
formation, yet the p89 fragment, which was detectable in
RAW 264.7 cells (Figure 1e), remained elusive in primary
BMM. Notably, we found that when cells were fed daily
(starting at day 1.5) instead of every 2 days as in Figure 2f and
g, p89 was readily detected 12 h after media replenishment in
WT, but not Artd1D214N/D214N cells (Figure 2h). These data
suggest that NLRP3 inflammasome-mediated ARTD1 clea-
vage at D214 is the first step in the processing of ARTD1, an
event that generates protein fragments which are subjected to
full proteolysis during osteoclastogenesis.
ARTD1 promotes the expression of repressors of OC
differentiation through mechanisms involving epigenetic
regulation. Given the emerging role of ARTD1 in transcrip-
tional regulation, we analyzed its effects on the expression of
transcription factors that regulate OC differentiation. The
expression of NFATc1 (Figure 3a) and Mitf (Figure 3b) was
up-regulated during the differentiation of WT cells as
expected, but not of ARTD1D214N-expressing cells. Conver-
sely, expression of the repressors of osteoclastogenesis,
IRF8 (Figure 3c), Lhx2 (Figure 3d), MafB (Figure 3e) and Id2
(Figure 3f) declined during the differentiation of WT cells,
but was remarkably up-regulated in cells expressing
ARTD1D214N. Interestingly, the levels of Blimp1 mRNA, a
presumed global negative regulator of anti-osteoclastogenic
molecules, including IRF8 and MafB10 were also lower in
Artd1D214N/D214N BMM (Figure 3g). Whereas ARTD1D214N
promoted the expression of the repressors of OC differentia-
tion, inhibition of ARTD1 activity by olap resulted in increased
Blimp1 expression (Figure 3h and i) and OC formation
(Supplementary Figure S3A) whereas IRF8 expression was
decreased (Figure 3j). These results, which are consistent
with our recent findings38 suggest that ARTD1 activity is an
important mechanism in ARTD1 negative regulation of
osteoclastogenesis.
Figure 1 ARTD1 PARylates proteins, including itself, and is degraded during OC formation via the proteasome pathway. (a) Western blot analysis using PAR antibody of
protein PARylation from 2% CMG-treated BMM cultures; bracket indicates areas of profound changes in PARylation. (b) Western blot analysis of the effect of vehicle, olap or velip
on 2% CMG-induced protein PARylation for 24 h in BMM cultures using PAR antibody. (c) Western blot analysis (using PAR antibody) of protein PARylation during OC
differentiation induced by 2% CMG and 100 ng/ml RANKL (experiment was run in duplicates). (d) Time-course effect of CMG-containing M-CSF on ARTD1 expression (h, hours
of CMG treatment). (e) Analysis of ARTD1 during OC differentiation from RAW 264.7 cells. (f) Analysis of ARTD1 expression during OC differentiation (d, days of exposure to
CMG and RANKL). (g) Analysis of ARTD1 during OC differentiation using GST-Af1521 macrodomains. On day 3, cultures were treated with olap, and the experiment was
terminated on day 4 (OC, 4 d, +olap). (h) Analysis of ARTD1 during OC differentiation by immunoprecipitation using PAR antibody. (i) Effect of the proteasome inhibitor, MG-132
on ARTD1 fate. Cultures were treated with 8 μM MG-132 on day 3 for 3 h prior to harvesting samples. Results are from the same gels, but the lanes were cut and pasted.
Incubation with MG-132 for43 h caused cytotoxicity. Data are representative of at least three independent experiments
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We employed chromatin immunoprecipitation (ChIP) to
elucidate the mechanisms of ARTD1 regulation of gene
expression during osteoclastogenesis. The expression
profile of WT and ARTD1D214N was indistinguishable,
suggesting that D214N substitution did not affect ARTD1
localization (Figure 4a and Supplementary Figure S3B).
Blimp1 protein induction was also attenuated during the
differentiation of ARTD1D214N-expressing cells compared with
Figure 2 Cleavage of ARTD1 at aspartate 214 is required for its degradation during osteoclastogenesis. BMM isolated from Artd1+/+ mice (a), Artd1D214N/D214N mice (b),
Nlrp3−/− mice (c), WT mice or mice expressing constitutively activated NLRP3 inflammasome (Nlrp3ca, d) were treated with vehicle or 100 ng/ml LPS for 3 h, and exposed to
vehicle or 5 mM ATP for the indicated times (min, minutes). Western blot analysis was carried out using ARTD1 antibody (top panel) or p89 ARTD1 antibody (middle panel, a).
The lanes from the same membranes were cut and pasted in d. (e) WTand Artd1D214N/D214N BMM were incubated with 2% CMG (BMM) or 2% CMG and 100 ng/ml RANKL for
2 days (pOC, 2d) or 4 days (OC, 4d), and mRNA expression was analyzed by qPCR. (f) Analysis of ARTD1 degradation during OC formation from Artd1+/+ or Artd1D214N/D214N
BMM. (g) Analysis of ARTD1 degradation during OC formation from Nlrp3+/+ or Nlrp3−/− BMM. (f) and (g) BMM were fed with 2% CMG or 2% CMG and 100 ng/ml RANKL every
2 days. (h) Analysis of ARTD1 cleavage and degradation during OC formation from BMM expressing ARTD1+/+ or ARTD1D214N. BMM were fed with 2% CMG and 100 ng/ml
RANKL every day starting at day 1.5, and samples were analyzed 12 h later (day 2 or 3) or 24 h later (day 2.5 or 3.5). Samples were analyzed by Western blot; a nonspecific faint
band around 89 kDa can be seen across samples (f–h). Data are representative of at least two independent experiments
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WT cells (Figure 4b, top panel) or RAW 264.7 cells
(Supplementary Figure S3C); these data were consistent with
the profile of Blimp1 mRNA expression (Figure 3g-i).
ARTD1 PARylation of histones can alter the modification of
these proteins by methylation or acetylation.19 Here, we found
that the patterns of global histone3lysine4 trimethylation
(H3K4me3), a mark of transcriptionally active chromatin
(Figure 4c), but not histone3lysine27 trimethylation
(H3K27me3), repressive mark (Figure 4d), was apparently
affected by ARTD1D214N expression at day 2 when we never
found evidence of ARTD1D214N processing (i.e., generation of
78 or 89 kDa fragment). We therefore focused on the former
modification to gain insight onto ARTD1 transcriptional
regulation during OC formation. PU.1, the transcription factor
that affects the early steps of OC formation,39 binds to Blimp1
promoter and positively regulates Blimp1 transcription.40
Given the key role of Blimp1 in osteoclastogenesis,10 we
determined the effect of ARTD1D214N on PU.1 regulation of
Blimp1 by focusing on BMM and OC precursors (pOC), which
express ARTD1 in contrast to OC. We found that PU.1
expression was increased slightly in WT pOC compared with
mutant pOC (Figure 4b, middle panel). Moreover, RANKL-
induced PU.1 recruitment to Blimp1 promoter in pOC in
WT cells was abolished in ARTD1D214N-expressing cells
(Figure 4e), consistent with decreased H3K4me3 at the
Blimp1 promoter in mutant cells (Figure 4f). Collectively, these
results indicate that ARTD1 inhibits OC formation by promot-
ing the expression of the repressors of this process while
interfering with the expression of master pro-osteoclastogenic
transcription factors such as Blimp1 through mechanisms
involving histone methylation.
Uncleavable ARTD1 causes a high bone mass phenotype
in mice. To determine the skeletal impact of constitutive
expression of ARTD1D214N,25 we analyzed the femora of
mice using micro-computed tomography (μCT). Bone mass
was significantly higher in Artd1D214N/D214N male mice at age
2 weeks (Figure 5a and b) and 8 weeks (Figure 5c and d) of
age compared with littermate WT male mice, consistent with
higher bone mineral density (BMD), increased number (Tb.N)
and thickness (Tb.Th) of the trabeculae, and decreased
trabecular space (Tb.Sp) in Artd1D214N/D214N mice
(Supplementary Figure S4A). This high bone mass pheno-
type was most likely related to defective bone resorption
as OC number (Oc.N/BS, Figure 5e and f) and surface
(Oc.S/BS, Figure 5g) were decreased in Artd1D214N/D214N
compared with WT mice, consistent with attenuated expres-
sion of OC markers, tartrate-resistant acid phosphatase
Figure 3 ARTD1 regulates transcription during OC formation. (a–g) BMM were treated with 2% CMG (BMM) or 2% CMG and 100 ng/ml RANKL for 3 days (OC, 3d) or 4 days
(OC, 4d). (h) BMM were treated with 2% CMG or 2% CMG and 100 ng/ml RANKL for 3 days in the presence of vehicle or 1 μM olap. (i and j) RAW 264.7 cells were treated with
vehicle or 100 ng/ml RANKL for 3 days in the presence of vehicle or 1 μM olap. RNA were isolated and analyzed by qPCR. Data were normalized to cyclophilin B (relative
expression) and expressed as mean± S.D. *Po0.05, Artd1+/+ versus Artd1D214N/D214N at each time-point (a–g), cells± olap versus BMM (h) or cells± olap versus RAW 264.7
cells (i and j)
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(TRAP) and cathepsin K (Supplementary Figure S4B). In
contrast, neither the dynamic indices of bone formation,
mineral apposition rate and bone formation rate
(Supplementary Figure S5A-D), the number of osteoblasts
(Supplementary Figure S5E) nor serum levels of the
biomarker of bone formation, procollagen type 1 N-terminal
propeptide (Supplementary Figure S5F) were different
between the two tested genotypes. Thus, the high bone
mass phenotype of Artd1D214N/D214N mice stems from
diminished OC development, but not bone formation.
Uncleavable ARTD1 causes defective osteoclast forma-
tion. The comparable gene expression levels of RANK,
osteoprotegerin and RANKL (Supplementary Figure S4B) in
bone samples from Artd1+/+ and Artd1D214N/D214N mice
suggests that ARTD1 regulates OC differentiation down-
stream of RANK signals. Thus, to directly test our hypothesis
that the high bone mass phenotype of Artd1D214N/D214N mice
was caused by defective OC development, we treated
BMM cultures with M-CSF or M-CSF and RANKL. M-CSF-
induced cell expansion was comparable between groups
(Figure 6a, top panels). In contrast, OC differentiation was
decreased490% in cultures of ARTD1D214N-expressing cells
(Figure 6a, bottom panels, and Figure 6b). TRAP (Figure 6c)
and cathepsin K (Figure 6d) mRNA expression was also
comparable between genotypes at day 2, but was significantly
reduced in Artd1D214N/D214N relative to WT cells by day 4 of
cultures. Artd1D214N/D214N BMM ultimately formed OC when
the cultures were maintained for 2 additional days (data not
shown), suggesting that OC formation from Artd1D214N/D214N
BMM was attenuated but not blocked, consistent with the
reduced number of OC in vivo in Artd1D214N/D214Nmice (Figure
5e and f). Thus, ARTD1D214N impairs the intrinsic ability of
BMM to efficiently undergo osteoclastogenesis in vitro.
Discussion
The expression of ARTD1 mRNA is maintained during OC
differentiation, yet WT ARTD1 protein is barely detectable in
OC, suggesting either mRNA translation inhibition by noncod-
ing RNA or ARTD1 protein degradation during OC formation.
Although ARTD1 is a target of microRNA such as miR-223,41
our results strongly support the latter scenario as ARTD1D214N
protein was consistently present in OC, and loss ofWTARTD1
Figure 4 ARTD1 regulates Blimp1 expression through epigenetic mechanisms. (a) Western blot analysis of WT ARTD1 and ARTD1D214N expression in BMM (Artd1D/D,
Artd1D214N/D214N). (b) Western blot analysis of Blimp1 and PU.1 expression in BMM, pOC (d2) or OC (d3). Results are from the same gels, but the lanes were cut and pasted).
(c) Analysis of global H3K4me3. (d) Analysis of global H3K27me3. (e) ChIP analysis of PU.1 binding to the Blimp1 promoter using IgG or PU.1 antibody for immunoprecipitation.
(f) ChIP analysis of H3K4me3 at the Blimp1 promoter. Data are expressed as mean± S.D. *Po0.05, BMM versus pOC, and are representative of three independent experiments
ARTD1 inhibits osteoclast differentiation
C Wang et al
6
Cell Death and Disease
in OC was attenuated upon acute pharmacological blockade
of the proteasome pathway. The notion that ARTD1 is
degraded in OC implies that this protein functions as an
intrinsic inhibitor of OC development, a view that is consistent
with the enhanced anti-osteoclastogenic potential of
degradation-resistant ARTD1D214N, and our other observa-
tions indicating that OC formation and bone resorption were
enhanced in Artd1-deficient mice.38 Thus, while ARTD1 is
dispensable in non-stress states in certain tissues, it plays a
non-redundant cell-context-dependent role in skeletal home-
ostasis. Although ubiquitination-mediated degradation of
ARTD1 in cancer cells was reported,28 our findings unravel a
novel concept in ARTD1 biology whereby degradation of this
protein is a prerequisite for full execution of OC differentiation
program.
ARTD1 PARylates itself in pOC in response to M-CSF
stimulation, and was subsequently degraded upon RANKL
exposure. Although further work is required to explore the link
between PARylation and ubiquitination of ARTD1 during OC
development, the fact that ARTD1 auto-PARylation occurs
early in BMM suggests that this modification may be a switch
that targets this protein for proteolysis. Consistent with this
concept, inhibition of ARTD1 activity, not only prevented
ARTD1 auto-modification, but also stopped its destruction. In
addition, a small fraction of WT ARTD1 that escapes
degradation is apparently not PARylated (Figure 2f and g,
Figure 5 ARTD1D214N causes high bone mass associated with decreased OC number. (a) Cross sections of 3 D μCT reconstruction of trabecular bones of distal femoral
metaphyses, and (b) trabecular bone mass (BV/TV) from 2-week-old Artd1+/+ and Artd1D214N/D214N male mice. Scale bar, 250 μm. (c) Cross sections of 3 D μCTreconstruction
of distal femoral metaphyses, and (d) BV/TV from 8-week-old Artd1+/+ and Artd1D214N/D214N male mice. Scale bar, 500 μm. (e) TRAP staining of bone sections; (i) and (ii)
represent a higher view of the area highlighted by the red box. (f) Histomorphometric analysis of OC number/bone surface (Oc. N/BS) fromWTand Artd1D214N/D214Nmice. (g) OC
surface/bone surface (Oc.S/BS). Quantitative data are from 8 Artd1+/+ mice and 5 Artd1D214N/D214N mice (b), and 4 Artd1+/+mice and 4 Artd1D214N/D214N mice (d, f and g). Data
are expressed as mean± S.D. *Po0.05
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OC 4 d). On the other hand, ARTD1 auto-PARylation
followed by cleavage and subsequent release from DNA
occurs in response to genotoxic insults,42 and is the presumed
mechanism that prevents ARTD1 overreaction and excessive
consumption of NAD+, an important source of cellular energy.
Thus, it is reasonable to speculate that promotion of ARTD1
PARylation by osteoclastogenic factors triggers the destruc-
tion of this enzyme to preserve NAD+ for energy metabolism
during osteoclastogenesis.
ARTD1 cleavage into p24 and p89 is a hallmark of
apoptosis, though the underlying mechanisms have not been
elucidated. Intriguingly, mice expressing ARTD1D214N develop
normally25 as do mice lacking this protein,43 suggesting that
ARTD1 cleavage is not essential for cell death. Thus, ARTD1
actions, which include modulation of the function of various
transcription factors such as NF-κB24 and NFATc122,23 are
more complex than originally thought. Here, we detected p89
during the early steps of osteoclastogenesis when ARTD1
was maximally PAR-conjugated, implying that PARylated
ARTD1 may be a high affinity substrate for caspases,
including caspase-7, which presumably cleaves ARTD1 in
the nucleus in a non-apoptotic manner as proposed
previously.35 Caspase-7 can be activated by caspase-1,
the catalytic component of the NLRP3 inflammasome,
a pathway that not only regulates OC differentiation and bone
resorption,37,44–49 but is also critical in ARTD1 proteolytic
processing during this process as demonstrated in this
study. Consistent with an important role of the NLRP3
inflammasome-ARTD1 axis in the regulation of osteoclasto-
genesis, pharmacological inhibition or deletion of caspase-1,
which attenuates ARTD1 degradation, inhibits OC
formation.37,38 Thus, despite the lack of the specific details
on the enzyme that cleaves ARTD1 in the OC lineage, our
results suggest a sequence of events whereby ARTD1 is
highly PARylated in BMM in response to M-CSF, cleaved
during RANKL-induced BMM lineage commitment, and finally
degraded in late pOC.
ARTD1D214N regulates the expression of anti-OC transcrip-
tion factors (IRF8, Id2, Lhx2 and MafB), but not of pro-OC
transcription factors (NFATc1 and Mitf) in BMM. These results
suggest that ARTD1D214N mainly regulates the expression of
the repressive molecules in BMM, and its inhibitory effects
on the expression of late OC markers such as cathepsin
K may be an indirect consequence of decreased OC
formation. Mechanistically, ARTD1 may regulate transcription
in BMM by binding to response elements or secondary hairpin
structures of gene regulatory regions. Besides the fact that the
role of ARTD1 gene regulation via binding to response
Figure 6 Osteoclastogenesis is defective in cells expressing ARTD1D214N. (a) WTand Artd1D214N/D214N BMM were incubated with 2% CMG (top panels) or 2% CMG and
100 ng/ml RANKL (bottom panels) for 4 days (4 d) to generate OC, and stained for TRAP activity. (b) OC number. (c and d) Quantitative PCR analysis of TRAP and cathepsin K
mRNA expression after treatment of cells with CMG (BMM) or CMG and RANKL for 2 and 4 days to generate pOC and OC, respectively. Data are representative of at least five
(a and b) or two independent experiments (c and d), and are expressed as mean± S.D. *Po0.05, Artd1+/+ versus Artd1D214N/D214N at day 4
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elements is still unclear, it is not conceptually obvious to
envision that ARTD1 directly regulates the expression of its
numerous targets, which are either pro or anti-osteo-
clastogenic. A plausible alternative is that ARTD1 affects
the function or accessibility to DNA response elements35 of
master transcription factors of OC development through
PARylation of these proteins and/or histones. A detailed
elucidation of such mechanisms is important, but is outside of
the scope of this manuscript. Nonetheless, consistent
with this scenario, we found that ARTD1D214N decreased
PU.1 binding to the promoter of the master repressor of anti-
osteoclastogenic factors, Blimp1,10 a response that correlated
with H3k4me3. Although PU.1 was not consistently induced in
WT pOC (data not shown) it cannot be ruled out that lack of
PU.1 induction in ARTD1D214N-expressing cells contributed
to the attenuated binding of PU.1 to Blimp1 promoter.
Collectively, our findings indicate that ARTD1 functions to
antagonize OC formation, an effect that is heightened in
ARTD1D214N, owing to its enhanced stability (Figure 7).
Advanced knowledge on ARTD1 biology revolves around its
role in cell survival and death in non-skeletal tissues. We have
discovered that ARTD1 impacts bone remodeling through its
ability to regulate OC differentiation, hence positioning ARTD1
as an important candidate to regulate bone loss in diseases.
Materials and Methods
Mice. Germline knock-in mice globally expressing an ARTD1 mutant rendered
uncleavable by D214N substitution (Artd1D214N/D214N mice) have been previously
described.25 Nlrp3−/− and Artd1− /− mice were purchased from the Jackson
Laboratory (Bass Harbor, ME, USA), and mice expressing constitutively activated
NLRP3 (NLRP3ca) inflammasome have also been previously described.44 Briefly,
Nlrp3fl(+/D301N) mice were crossed with LysM-Cre mice to obtain Nlrp3ca mice.
Nlrp3fl(+/D301N); Artd1D214N were mated with LysM-Cre;Artd1D214N mice to generate
Nlrp3ca; Artd1D214N/D214N mice. All mice were on the C57BL6 background, and
mouse genotyping was performed by PCR. All procedures were approved by the
Institutional Animal Care and Use Committee of Washington University School of
Medicine in St. Louis.
Bone mass and microstructure. Femoral bone structure was analyzed by
μCT system (μCT 40; Scanco Medical AG, Zurich, Switzerland) as described
previously.37 Briefly, femora from 2-week-old and 8-week-old male mice were
stabilized in 2% agarose gel, and μCT scans at 55 kVp were taken along the length
of the femur as described previously.37 The volume of interest analyzed was located
just proximal to the growth plate, spanning a height of 350 μm each for the
metaphyseal region.
Histology and histomorphometry. Mice were labeled twice by injection of
calcein (15 mg/kg i.p.; Sigma-Aldrich, St. Louis, MO, USA) 5 and 2 days before
euthanasia, which was performed under light anesthesia by exsanguination through
dorsal aortic puncture. Blood was collected and the serum stored at − 80 °C for
later assays. Tissue samples were processed as described previously.37 Briefly,
long bones were fixed in 10% formalin, decalcified in 14% (w/v) EDTA pH 7.2 for
10–14 days at room temperature (RT), embedded in paraffin, sectioned at 5 μm
thickness and mounted on glass slides. Stained sections with H&E or TRAP were
used for the analysis of osteoblasts and OC, respectively, as described previously.37
For dynamic histomorphometric analysis, bones were fixed in 70% ethanol for 24 h,
left undecalcified and embedded in methyl methacrylate. Photographs were taken
using nanozoomer (Hamamatsu, Hamamatsu City, Japan).
OC formation. Bone marrow macrophages (BMM) were obtained by culturing
mouse bone marrow cells in culture media containing a 1 : 25 dilution of
supernatant from the fibroblastic cell line, CMG 14-12, as a source of M-CSF,34
a mitogenic factor for BMM, for ~ 5 days in a 10-cm dish as described previously.37
Nonadherent cells were removed by vigorous washes with PBS, and adherent BMM
were detached with trypsin-EDTA, plated at 5–10 × 103/well in a 96-well plate in
culture media containing a 1 : 50 dilution of CMG and 100 ng/ml RANKL,
a required cytokine for OC differentiation. For OC formation from RAW 264.7 cells,
3 × 103 cells/well in a 96-well plate were treated with 100 ng/ml RANKL. Media with
supplements were changed every other day, and maintained at 37 °C in
a humidified atmosphere of 5% CO2 in air.
TRAP staining. Cytochemical staining for TRAP was used to identify OC as
described previously.37 Briefly, cells in a 96 well plate were fixed with 3.7%
formaldehyde and 0.1% Triton X-100 for 10 min at RT. The cells were rinsed with
water and incubated with the TRAP staining solution (leukocyte acid phosphatase
kit, Sigma-Aldrich) at RT for 30 min. Under light microscopy, multinuclear TRAP
positive cells with at least 3 nuclei were scored as OC.
mRNA expression analysis. Total RNA was harvested from cells using
RNeasy Plus Mini Kit (Qiagen, Hilden, Germany). Complementary DNA was then
synthesized with iScript reverse transcription kit (Bio-Rad, Hercules, CA, USA) and
quantified using primers listed in Supplementary Table 1. Gene expression was
analyzed by SYBR Green gene expression assay (Applied Biosystems, Waltham,
MA, USA).
Chromatin immunoprecipitation. Chromatin immunoprecipitation (ChIP)
was carried out using standard procedures. Briefly, cells were washed, scraped with
ice-cold PBS, centrifuged, and the pellets were sonicated to generate ChIP DNA
fragments (200–600 bp), which were cross-linked using standard protocols.
Samples were incubated with either normal rabbit IgG, H3 antibody (Abcam,
Cambridge, UK), H3K4me3 (Millipore, Billerica, MA, USA) or PU.1 antibody (Santa
Cruz, Dallas, TX, USA) for overnight at 4 °C under rotation, followed by incubation
with protein A/G plus agarose beads for 2–3 h at 4 °C. After several washes,
precipitated chromatin complexes were eluted, and uncrosslinked overnight at 65 °C
with in buffer containing 5 M NaCl, followed by treatment with RNase A and
proteinase K. DNA was extracted with QiaQuick PCR purification kit (Qiagen), and
quantified by qPCR using primers listed in Supplementary Table S1.
Figure 7 A model of ARTD1 regulation of OC formation. In the absence of
M-CSF and RANKL, the NLRP3 inflammasome is minimally active in Artd1+/+ and
Artd1D214N/D214N cells (a and a’). As a result, the epigenetic action of ARTD1D214N
(ARTD1D) and WT ARTD1 to a lesser extent, promotes the expression of the
repressors of OC differentiation, thereby inhibiting this process. In WT cells, NLRP3
inflammasome activation by M-CSF and RANKL cues leads to ARTD1 auto-
PARylation, cleavage and subsequent degradation; this restrains ARTD1-dependent
chromatin alterations, and enables the expression of activators and promotion of OC
maturation (b). In contrast, ARTD1D is resistant to cleavage and degradation (b’).
Its sustained epigenetic action maintains the expression of OC repressors, thereby,
inhibiting OC formation
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Expression and purification of Af1521 macrodomains. Af1521
macrodomains were generated as described previously.36 Briefly, BL21 bacteria
were transformed with the expression plasmid pGEX containing GST-tagged
Af1521, which was purified using Glutathione Sepharose 4B (GE Healthcare). The
purity of the fusion protein, resuspended in a buffer containing 50 mM Tris-HCl,
pH7.5, 150 mM NaCl and1 mM DTT was monitored by staining the gel with
coomassie blue after SDS-PAGE.
Pull-down, immunoprecipitation andWestern blot analyses. Cells
were lyzed with RIPA buffer (50 mM Tris, 150 mM NaCl, 1 mM EDTA, 0.5%
NaDOAc, 0.1% SDS, 1.0% NP-40), and the proteins were quantified and used for
immunoprecipitation and/or Western blot analysis. All lysis buffers were
supplemented with phosphatase inhibitors (2 mM NaVO4, 10 mM NaF and 1 mM
PMSF) and Complete Protease Inhibitor Cocktail (Roche, Basel, Switzerland).
Protein concentrations were determined by the BioRad method. For the pull-down
analysis, 800 μg proteins were incubated with 20 μg Af1521, followed by washing
the beads four times. For the immunoprecipitation studies, 800 μg proteins were
incubated with 10 μg PAR antibody followed by incubation with 60 μl protein A/G-
agarose (Santa Cruz Biotechnology) and the pellets were washed four times.
Proteins were subjected to SDS-PAGE on 4–12% NuPAGE gels (Invitrogen).
Proteins were transferred onto nitrocellulose membranes, and incubated with
ARTD1 antibody (1 : 1000, Cell Signaling Technologies, Danvers, MA, USA),
NLRP3 antibody (1 : 1000, Adipogen, San Diego, CA, USA), β-actin antibody
(1 : 50 000, Sigma), HSP90 antibody (1 : 2000, Santa Cruz Biotechnology), tubulin
antibody (1 : 1000, Santa Cruz Biotechnology ) or GAPDH antibody (1 : 1000,
Santa Cruz Biotechnology) for 2 h at room temperature, followed by 1 h incubation
with secondary goat anti-mouse IRDye 800 (Rockland, Limerick, PA, USA) or goat
anti-rabbit Alexa-Fluor 680 (Molecular Probes, Eugene, OR, USA), respectively. The
results were visualized using Li-Cor Odyssey Infrared Imaging System (Li-Cor,
Lincoln, NE, USA).
Statistical analysis. Statistical significance was assessed by Student’s t test
for independent samples, unless otherwise stated.
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